Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients ...

For patients unable to withstand the increased toxicity of a four-drug regimen, the two most commonly used triplet regimens ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with ...

The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

In fact, all people with multiple myeloma will have a relapse or become resistant to treatment at some point. 1 Recent data from newly diagnosed patients show that about 10% of those starting a novel ...

Kathy Giusti was diagnosed with multiple myeloma in 1996, when she was a 37-year-old executive at the drug company G.D. Searle. She was told she had three years to live. Twenty-eight years later ...